MediPoint: Drug-Eluting Balloons - Current and Fuutre Players

  • September 2013
  • -
  • Global Data
  • -
  • 178 pages

MediPoint: Drug-Eluting Balloons - Current and Fuutre Players

Summary

GlobalData has released its medical device report, “MediPoint: Drug-Eluting Balloons - Current and Fuutre Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the steadily growing Drug-Eluting Balloons (DEB) Market. In the report, the adoption of DEB for coronary and peripheral applications in the lower extremity including in-stent restenosis, bifurcation lesions, small vessel disease, femoropopliteal artery and below-the-knee lesions, chronic total occlusions, acute myocardial infarction and lesions in diabetics has been evaluated.


The report identifies and analyzes the key companies shaping and driving the global DEB market. The report provides insight into the competitive drug-eluting balloon landscape, including new companies entering the market and pipeline products in development. This report is built using data and information sourced from proprietary databases, secondary sources and primary research interviews and survey with leading Interventional Cardiologists and Interventional Radiologists, with in-house analysis conducted by GlobalData’s team of industry experts.

Scope

- Investigation of current and future market competition for DEB for coronary applications and peripheral applications in the lower extremity.
- Competitor assessment including device approval analysis.
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of the device sector through market impact analysis, future market scenario and company analysis.
- Direct quotes from Key Opinion Leaders (KOL) as well as interventional cardiologists and radiologists already using DEB in clinical practice.

Reasons to buy

- Gain a high level view of the trends shaping and driving the DEB market for coronary applications and peripheral applications in the lower extremity.
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
- Take a comprehensive look at the market’s device pipeline and identify promising, paradigm-shifting products.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market.

Table Of Contents

Table of Contents

1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 11
2 Introduction 12
2.1 Catalyst 13
3 Competitive Assessment 15
3.1 Overview 15
3.2 Product Profiles by Company 17
3.2.1 Aachen Resonance 18
3.2.2 B. Braun 20
3.2.3 Biotronik 27
3.2.4 Blue Medical 30
3.2.5 Cardionovum 36
3.2.6 C.R. Bard 41
3.2.7 Concept Medical Research 47
3.2.8 Cook Medical 51
3.2.9 Eurocor 53
3.2.10 Medrad (Bayer Healthcare) 68
3.2.11 Medtronic 70
3.2.12 Minvasys 78
4 Pipeline Products 81
4.1 Overview 81
4.2 Pipeline by Stage of Development 82
4.3 Pipeline Product Profiles 84
4.3.1 NF-?B Decoy Oligo DEB 84
4.3.2 Drug-Coated AngioSculpt 86
4.3.3 BioPath 89
4.3.4 BioStream 90
4.3.5 Boston Scientific Drug-Coated Balloon 91
4.3.6 Coroflex DEBlue 92
4.3.7 Covidien Drug-Coated Balloon 94
4.3.8 DSM Biomedical and Caliber Therapeutics DEB 96
4.3.9 Elixir Medical Corporation DCB 97
4.3.10 LifeTech Scientific Corporation DEB 97
4.3.11 Micell Technologies Drug-Coated Balloon 97
4.3.12 Drug-Coated Chocolate DEB 99
4.3.13 Passeo-18 Lux 101
4.3.14 Vascular Nanotransfer Technologies Drug-Coated Balloon 102
4.3.15 WOMBAT DCB 103
5 Current and Future Players 105
5.1 Overview 105
5.2 Trends in Corporate Strategy 106
5.3 Company Profiles 109
5.3.1 Aachen Resonance 109
5.3.2 AnGes MG 110
5.3.3 AngioScore 112
5.3.4 AVIDAL Vascular 114
5.3.5 B. Braun 116
5.3.6 Biosensors International 118
5.3.7 Biotronik 120
5.3.8 Blue Medical 122
5.3.9 Boston Scientific Corporation 124
5.3.10 Caliber Therapeutics 126
5.3.11 Cardionovum 128
5.3.12 Concept Medical Research 130
5.3.13 Cook Medical 132
5.3.14 Covidien 134
5.3.15 C.R. Bard 136
5.3.16 DSM Biomedical 138
5.3.17 Elixir Medical Corporation 140
5.3.18 Eurocor 142
5.3.19 LifeTech Scientific Corporation 144
5.3.20 Medtronic 146
5.3.21 Micell Technologies 148
5.3.22 Minvasys 149
5.3.23 TriReme Medical 151
5.3.24 Vascular Nanotransfer Technologies 153
6 Appendix 155
6.1 Bibliography 155
6.2 Abbreviations 165
6.3 Report Methodology 168
6.3.1 Overview 168
6.3.2 Coverage 168
6.3.3 Secondary Research 169
6.3.4 Forecasting Methodology 169
6.4 Physicians and Specialists Included in this Study 171
6.5 Physician Survey 174
6.6 About the Authors 175
6.6.1 Analysts 175
6.6.2 Global Head of Healthcare 176
6.7 About MediPoint 177
6.8 About GlobalData 177
6.9 Disclaimer 177




List of Tables

Table 1: Global DEB Market ($m) for Treating Coronary and Peripheral Artery Disease, 2012 15
Table 2: Marketed DEB Products 17
Table 3: Elutax SV Product Portfolio 18
Table 4: Elutax SV SWOT Analysis, 2013 20
Table 5: SeQuent Please Product Portfolio 21
Table 6: SeQuent Please SWOT Analysis, 2013 26
Table 7: Pantera Lux Product Portfolio 27
Table 8: Pantera Lux SWOT Analysis, 2013 29
Table 9: Pioneer Product Portfolio 30
Table 10: Pioneer SWOT Analysis, 2013 32
Table 11: Protege Product Portfolio 33
Table 12: Protege SWOT Analysis, 2013 36
Table 13: Restore DEB Product Portfolio 37
Table 14: Restore DEB SWOT Analysis, 2013 38
Table 15: Legflow DEB Product Portfolio 39
Table 16: Legflow DEB SWOT Analysis, 2013 41
Table 17: Lutonix Product Portfolio 42
Table 18: Lutonix SWOT Analysis, 2013 47
Table 19: Magic Touch Product Portfolio 48
Table 20: Magic Touch SWOT Analysis, 2013 50
Table 21: Advance 18 PTX Product Portfolio 51
Table 22: Advance 18 PTX SWOT Analysis, 2013 53
Table 23: Dior Product Portfolio 54
Table 24: Dior SWOT Analysis, 2013 60
Table 25: Freeway Family of DEB Product Portfolio 61
Table 26: Freeway Family of DEB SWOT Analysis, 2013 64
Table 27: Magical Product Portfolio 65
Table 28: Magical SWOT Analysis, 2013 67
Table 29: Cotavance Product Portfolio 68
Table 30: Cotavance SWOT Analysis, 2013 70
Table 31: IN.PACT Family DEB Product Portfolio 71
Table 32: IN.PACT SWOT Analysis, 2013 78
Table 33: Danubio Product Portfolio 79
Table 34: Danubio SWOT Analysis, 2013 80
Table 35: Global DEB Pipeline Products 83
Table 36: NF-?B Decoy Oligo DEB SWOT Analysis, 2013 86
Table 37: AngioSculpt SWOT Analysis, 2013 88
Table 38: BioPath SWOT Analysis, 2013 90
Table 39: BioStream SWOT Analysis, 2013 91
Table 40: Boston Scientific DEB SWOT Analysis, 2013 92
Table 41: Coroflex DEBlue SWOT Analysis, 2013 94
Table 42: Covidien DCB SWOT Analysis, 2013 96
Table 43: Micell Technologies’ DCB SWOT Analysis, 2013 98
Table 44: Drug-Coated Chocolate DEB SWOT Analysis, 2013 100
Table 45: Passeo-18 Lux SWOT Analysis, 2013 102
Table 46: Vascular Nanotransfer Technologies DCB SWOT Analysis, 2013 103
Table 47: WOMBAT DCB SWOT Analysis, 2013 104
Table 48: Aachen Resonance Company Profile 109
Table 49: Aachen Resonance, Marketed DEB Product 110
Table 50: Aachen Resonance SWOT Analysis, 2013 110
Table 51: AnGes MG Company Profile 111
Table 52: AnGes MG, Pipeline DEB Product 112
Table 53: AnGes MG SWOT Analysis, 2013 112
Table 54: AngioScore Company Profile 113
Table 55: AngioScore, Pipeline DEB Product 113
Table 56: AngioScore SWOT Analysis, 2013 114
Table 57: AVIDAL Vascular Company Profile 114
Table 58: AVIDAL Vascular, Pipeline DEB Product 115
Table 59: AVIDAL Vascular SWOT Analysis, 2013 116
Table 60: B. Braun Company Profile 116
Table 61: B. Braun, Marketed and Pipeline DEB Products 117
Table 62: B. Braun SWOT Analysis, 2013 118
Table 63: Biosensors International Company Profile 119
Table 64: Biosensors International, Pipeline DEB Products 119
Table 65: Biosensors International SWOT Analysis, 2013 120
Table 66: Biotronik Company Profile 121
Table 67: Biotronik, Marketed and Pipeline DEB Products 121
Table 68: Biotronik SWOT Analysis, 2013 122
Table 69: Blue Medical Company Profile 123
Table 70: Blue Medical, Marketed DEB Products 124
Table 71: Blue Medical SWOT Analysis, 2013 124
Table 72: Boston Scientific Corporation Company Profile 125
Table 73: Boston Scientific Corporation, Pipeline DEB Product 125
Table 74: Boston Scientific Corporation SWOT Analysis, 2013 126
Table 75: Caliber Therapeutics Company Profile 126
Table 76: Caliber Therapeutcs, Pipeline DEB Product 127
Table 77: Caliber Therapeutics SWOT Analysis, 2013 128
Table 78: Cardionovum Company Profile 128
Table 79: Cardionovum, Marketed DEB Products 129
Table 80: Cardionovum SWOT Analysis, 2013 130
Table 81: Concept Medical Research Company Profile 130
Table 82: Concept Medical Research, Marketed DEB Product 131
Table 83: Concept Medical Research SWOT Analysis, 2013 132
Table 84: Cook Medical Company Profile 132
Table 85: Cook Medical, Marketed DEB Product 133
Table 86: Cook Medical SWOT Analysis, 2013 134
Table 87: Covidien Company Profile 135
Table 88: Covidien, Pipeline DEB Product 135
Table 89: Covidien SWOT Analysis, 2013 136
Table 90: C.R. Bard Company Profile 136
Table 91: C.R. Bard, Marketed DEB Products 137
Table 92: C.R. Bard SWOT Analysis, 2013 138
Table 93: DSM Biomedical Company Profile 139
Table 94: DSM Biomedical, Pipeline DEB Product 139
Table 95: DSM Biomedical SWOT Analysis, 2013 140
Table 96: Elixir Medical Corporation Company Profile 140
Table 97: Elixir Medical Corporation, Pipeline DEB Product 141
Table 98: Elixir Medical Corporation SWOT Analysis, 2013 141
Table 99: Eurocor Company Profile 142
Table 100: Eurocor, Marketed DEB Products 143
Table 101: Eurocor SWOT Analysis, 2013 143
Table 102: LifeTech Scientific Corporation Company Profile 144
Table 103: LifeTech Scientific, Pipeline DEB Product 145
Table 104: LifeTech Scientific SWOT Analysis, 2013 145
Table 105: Medtronic Company Profile 146
Table 106: Medtronic, Marketed DEB Products 147
Table 107: Medtronic SWOT Analysis, 2013 147
Table 108: Micell Technologies Company Profile 148
Table 109: Micell Technologies, Pipeline DEB Product 149
Table 110: Micell Technologies SWOT Analysis, 2013 149
Table 111: Minvasys Company Profile 150
Table 112: Minvasys, Marketed DEB Product 150
Table 113: Minvasys SWOT Analysis, 2013 151
Table 114: TriReme Medical Company Profile 151
Table 115: TriReme Medical, Pipeline DEB Product 152
Table 116: TriReme Medical SWOT Analysis, 2013 153
Table 117: Vascular Nanotransfer Technologies Company Profile 153
Table 118: Vascular Nanotransfer Technologies, Pipeline DEB Product 154
Table 119: Vascular Nanotransfer Technologies SWOT Analysis, 2013 154
Table 120: Physicians Surveyed, By Country 174

1.2 List of Figures
Figure 1: Global DEB Market Share for Treating Peripheral Artery Disease in the Lower Extremity, 2012 16
Figure 2: Image of the Protege DEB 34
Figure 3: Global DEB Pipeline Products by Stage of Development, 2013 82
Figure 4: AngioSculpt Scoring Balloon Expansion Profile 87
Figure 5: Drug-Coated Chocolate DEB 99
Figure 6: DEB Market for Treating CAD and PAD in the Lower Extremity, Company Share (%), 2012 105
Figure 7: DEB Market for Each Type of Disease, Company Share (%), 2012 107

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • August 2014
  • by Global Data

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented ...

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 10 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary During the forecast period from 2012-2022, the growth of the UC market will be driven largely ...

Cancer Vaccines: Technologies and Global Markets

Cancer Vaccines: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • Dec 2014
  • by BCC Research

REPORT HIGHLIGHTS The global market for cancer vaccines was about $4.5 billion in 2013. This market reached about $4.0 billion in 2014 and is expected to reach $4.3 billion in 2019, registering a compound ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.